丙型肝炎病毒小鼠实验模型的研究进展

兰海云; 汪爱勤; 尹文

丙型肝炎病毒小鼠实验模型的研究进展

第四军医大学基础部中心实验室

基金项目:

国家“863”计划专题(2007AA02Z154)；国家自然科学基金(30872218)；陕西省科技攻关计划(2010K15-03-04)；

详细信息

中图分类号: R512.63;R-332
计量
- 文章访问数: 2789
- HTML全文浏览量: 23
- PDF下载量: 1356
- 被引次数: 0
出版历程
- 出版日期: 2011-01-20

Advance in the research of experimental mouse model for hepatitis C virus

Research funding:

摘要

摘要:
丙型肝炎病毒(HCV)感染是导致慢性肝病的主要原因。大部分HCV感染者呈持续性感染,这与肝硬化和肝细胞癌紧密相关。近十年来,许多学者通过不懈的努力建立了各种行之有效的小鼠实验模型,基于这些模型的研究极大地丰富和加深了对HCV感染、致病、免疫等方面分子机理的认识,同时也极大地促进了新的抗病毒策略和特异药物筛选的发展。本文就目前最常见和未来有应用前景的两类小鼠实验模型作一综述。
- 模型,动物 /
- 肝炎,丙型
Abstract:
Hepatitic C virus (HCV) infection is the main cause of chronic liver disease.Most of the infected individuals develop persistent infection which is closely related to liver cirrhosis and hepatocellular carcinoma.In the last decade, many researchers spared no efforts to establish varieties of mouse models, which enrich and deepen the view of molecular mechanisms of HCV infection, pathogenicity and immunity.The new anti–viral strategies and specific drug screening were simultaneously developed.In this paper, two types of most common experimental mouse models are reviewed.
- models /
- animal

HTML全文

参考文献(24)

[1]Wu GY, Konishi M, Walton CM, et al.A novel im-munocompetent rat model of HCV infection and hepatitis[J].Gastroenterology, 2005, 128 (5) :1416-1423.

[2]Galun E, Burakova T, Ketzinel M, et al.Hepatitis C virus viremia in SCID-BNX mouse chimera[J].J Infect Dis, 临床肝胆病杂志2011年第27卷第1期1995, 172 (1) :25-30.

[3]Maeda N, Watanabe M, Okamoto S, et al.Hepatitis C virus infection in human liver tissue engrafted in mice with an infectious molecular clone[J].Liver Int, 2004, 24 (3) :259-267.

[4]Mercer DF, Schiller DE, Elliott JF, et al.Hepatitis C virus replication in mice with chimeric human livers[J].Nat Med, 2001, 7 (8) :927-933.

[5]Walters KA, Joyce MA, Thompson JC, et al.Host-specific response to HCV infection in the chimeric SCID-beige/Alb-uPA mouse model:role of the innate antiviral immune response[J].PLoS Pathog, 2006, 2 (6) :e59.

[6]Turrini P, Sasso R, Germoni S, et al.Development of humanized mice for the study of hepatitis C virus infection[J].Transplant Proc, 2006, 38 (4) :1181-1184.

[7]Vanwolleghem T, Bukh J, Meuleman P, et al.Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain[J].Hepatology, 2008, 47 (6) :1846-1855.

[8]Law M, Maruyama T, Lewis J, et al.Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge[J].Nat Med, 2008, 14 (1) :25-27.

[9]Meuleman P, Hesselgesser J, Paulson M, et al.Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo[J].Hepatology, 2008, 48 (6) :1761-1768.

[10]Moriishi K, Mochizuki R, Moriya K, et al.Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis[J].Proc Natl Acad Sci U S A, 2007, 104 (5) :1661-1666.

[11]Kamegaya Y, Hiasa Y, Zukerberg L, et al.Hepatitis C v-irus acts as a tumor accelerator by blocking apoptosis in a mouse model of hepatocarcinogenesis[J].Hepatology, 2005, 41 (3) :660-667.

[12]Frelin L, Brenndorfer ED, Ahlen G, et al.The hepatitis C virus and immune evasion:non-structural 3/4A transgenic mice are resistant to lethal tumour necrosis factor alpha mediated liver disease[J].Gut, 2006, 55 (10) :1475-1483.

[13]Ahéln G, Derk E, Weiland M, et al.Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes[J].Gut, 2009, 58 (4) :560-569.

[14]Wang AG, Lee DS, Moon HB, et al.Non-structural 5A protein of hepatitis C virus induces a range of liver pathology in transgenic mice[J].J Pathol, 2009, 219 (2) :253-262.

[15]Kriegs M, Bürckstümmer T, Himmelsbach K, et al.The hepatitis C virus non-structural NS5A protein impairs both the innate and adaptive hepatic immune response in vivo[J].J Biol Chem, 2009, 284 (41) :28343-28351.

[16]Masciopinto F, Freer G, Burgio VL, et al.Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection[J].Virology, 2002, 304:187-196.

[17]Ploss A, Evans MJ, Gaysinskaya VA, et al.Human occ-ludin is a hepatitis C virus entry factor required for infection of mouse cells[J].Nature, 2009, 457 (7231) :882-886.

[18]Ploss A, Rice CM.Towards a small animal model for hepatitis C[J].EMBO Rep, 2009, 10 (11) :1220-1227.

[19]Bitzegeio J, Bankwitz D, Hueging K, et al.Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors[J].PLoS Pathog, 2010, 6 (7) :e1000978.

[20]Legrand N, Ploss A.Humanized mice for modeling hu-man infectious disease:challenges, progress, and outlook[J].Cell Host Microbe, 2009, 6 (1) :5-9.

[21]Strowig T, Gurer C, Ploss A.Priming of protective T cell responses against virus-induced tumors in mice with human immune system components[J].J Exp Med, 2009, 206 (6) :1423-1434.

[22]Wakita T, Taya C, Katsume A, et al.Efficient conditional transgene expression in hepatitis C virus cDNA transgenic mice mediated by the Cre/loxP system[J].J Biol Chem, 1998, 273 (15) :9001-9006.

[23]Satoh K, Takahashi H, Matsuda C, et al.Natural killer cells target HCV core proteins during the innate immune response in HCV transgenic mice[J].J Med Virol, 2010, 82 (9) :1545-1553.

[24]Stieger K, Belbellaa B, Le Guiner C, et al.In vivo gene regulation using tetracycline-regulatable systems[J].Adv Drug Deliv Rev, 2009, 61 (7-8) :527-541.

施引文献

资源附件(0)

访问统计